Jared S. Hopkins
Wall Street Journal
New York, NY, United States
Contact Jared
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Jared:
Bausch + Lomb’s CEO Inks First Big Deal Since Return
Eye-care company agreed to pay $1.75 billion for Novartis’s dry-eye treatment Xiidra. → Read More
New $2.9 Million Gene Therapy Promises to Remake Hemophilia Treatment
BioMarin’s gene therapy is the first to win Food and Drug Administration approval for adults with the most common form of the bleeding disorder. → Read More
New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy
The shot won FDA approval as a new study finds a 14-percentage-point drop in vaccine confidence since the Covid pandemic. → Read More
Next Covid Boosters to Target New Strain
Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S. → Read More
Pfizer in talks to acquire Seagen in deal likely valued at more than $30B
Pfizer, one of the world’s biggest pharmaceutical companies, is flush with cash from the COVID-19 pandemic and hopes the Seagen acquisition will help grow revenue. → Read More
FDA Wants Fall Covid-19 Boosters to Target Omicron Subvariants BA.4 and BA.5
The agency has told vaccine makers to target the rapidly emerging Omicron subvariants BA.4 and BA.5, as well as the ancestral strain of the virus. → Read More
Pfizer Seeks FDA’s Full Approval for Paxlovid Covid-19 Pill
Approval of Paxlovid, which has been available under an Food and Drug Administration authorization for use during the pandemic, would allow Pfizer to market and sell it commercially. → Read More
Pfizer’s Omicron-Targeting Covid-19 Vaccines Generate Stronger Immune Response
One shot that was tested targeted Omicron specifically, while another was modified to work against the strain and the original virus. → Read More
Pfizer Asks FDA to Authorize Its Covid-19 Vaccine for Children Under 5
The request for clearance of a three-dose series could lead to the young age group gaining access to Covid-19 shots as soon as this month. → Read More
Paxlovid Becomes Household Name for Covid-19 Patients
Pfizer’s antiviral drug sees an uptick in prescriptions, as more doctors order patients take it over the Merck-Ridgeback pill called Lagevrio. → Read More
Pfizer to Sell Vaccines, Drugs at Low Prices to Poorer Countries
The arrangement means that some of the drugs that carry list prices of tens of thousands of dollars a year in the U.S. would be substantially less for the low-income countries to buy, according to Pfizer. → Read More
Covid-19 Vaccine and Drug Sales, Once Booming, Plateau
Merck, J&J and some other drugmakers are dialing back sales estimates now that supplies are ample and many people are vaccinated. → Read More
Three Doses of Pfizer’s Covid-19 Vaccine 80% Effective in Young Children, Company Says
The three shots were found effective in preventing symptomatic Covid-19 in children 6 months to 5 years, an early analysis of study data found. → Read More
Pfizer’s Covid-19 Booster Cleared for 5- to 11-Year-Olds
The authorization by U.S. health regulators expands booster access to about 28 million youngsters. → Read More
Some Covid-19 Patients Relapse After Taking Paxlovid, Puzzling Doctors
Some patients who took Paxlovid to treat Covid-19 have experienced cold-like symptoms such as sore throat and cough two weeks after appearing to get better, puzzling physicians and researchers trying to stay ahead of the virus. → Read More
Pfizer to Buy Rest of Biohaven for $11.6 Billion
The move to acquire the New Haven, Conn., biopharmaceutical company will give the New York drugmaker full ownership of the Nurtec migraine franchise. → Read More
Pfizer Sales Soar on Covid-19 Vaccine Sales
Demand for the company’s antiviral pill has increased as Covid-19 cases have jumped. → Read More
Pfizer’s Covid-19 Pill Failed Study Testing Its Preventive Use
Paxlovid, authorized to treat people at high risk of severe disease within a few days of infection, wasn’t found to prevent symptomatic infections in a study. → Read More
FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease
U.S. health regulators approved a pill from Bristol-Myers Squibb, the first to treat a genetic heart disease that is the most common cause of sudden cardiac death in people under age 35. → Read More
Pfizer Asks FDA to Authorize Covid-19 Booster for 5- to 11-Year-Olds
Pfizer Inc. and partner BioNTech SE said earlier this month that a third shot safely generated a strong immune response in the youngsters. → Read More